Transdermal beta-blocker therapy in essential hypertension.
Transdermal drug delivery has been applied to various agents in an effort to decrease the frequency of drug administration and increase the patients compliance. In our study, we demonstrated that transdermal application of a beta-blocker (20 mg mepindolol) in patients with essential hypertension led to effective blood pressure lowering effect within 1 week (160.1 +/- 6.1 mm Hg/95.8 +/- 8.3 mm Hg vs 136.8 +/- 7.2 mm Hg/84.3 +/- 5.0 mm Hg; P less than 0.05). A controlled study of transdermal versus oral beta-blocker administration in hypertensives is necessary before this new therapeutic system is introduced in antihypertensive treatment.
D000279:Administration, Cutaneous; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003875:Drug Eruptions; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010869:Pindolol / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; C015340:mepindolol; D010869:Pindolol